Showing 3871-3880 of 8129 results for "".
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Microneedling Treatment Reduces Periorbital Wrinkle Severityhttps://practicaldermatology.com/news/microneedling-treatment-reduces-periorbital-wrinkle-severity/2487121/A prospective clinical study presented at the 2026 Music City SCALE Annual Meeting demonstrated significant improvement in periorbital wrinkles following treatment with the SkinStylus SteriLock MicroSystem (Hydrafacial LLC). The study evaluated the safety and effic
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://practicaldermatology.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual
- Text-Messaging Program Improves Cardiovascular Risk Behaviors in Psoriasishttps://practicaldermatology.com/news/text-messaging-program-improves-cardiovascular-risk-behaviors-in-psoriasis/2487068/Structured text-messaging interventions were associated with an improvement cardiovascular risk-related behaviors and patient activation in adults with psoriasis, according to new study results published online in JAMA Dermatology.
- Iron Oxides in Tinted Sunscreens May Improve Hyperpigmentation Protection: Studyhttps://practicaldermatology.com/news/iron-oxides-in-tinted-sunscreens-may-improve-hyperpigmentation-protection-study/2487035/A literature review and product analysis published in the Journal of Drugs in Dermatology highlighted growing evidence supporting the use of iron oxides in tinted sunscreens for managing hyperpigmentation, while also identif
- Long-Term Dupilumab Use Linked to Delayed Relapse in AD: Studyhttps://practicaldermatology.com/news/long-term-dupilumab-use-linked-to-delayed-relapse-in-ad-study/2487027/Patients with moderate-to-severe atopic dermatitis (AD) treated with dupilumab experienced durable symptom control and delayed relapse with long-term therapy, according to a real-world retrospective study published in the Journal
- Report: One-Third of Patients With Vitiligo Receive No Follow-Up Treatmenthttps://practicaldermatology.com/news/report-one-third-of-patients-with-vitiligo-receive-no-follow-up-treatment/2487004/Almost one-third of patients with vitiligo did not receive treatment following diagnosis, according to a report in JAMA Dermatology.
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients